Atlas Trials

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Clinical trial NCT06185673 · RECRUITING

Trial details

NCT number
NCT06185673
Sponsor
Benitec Biopharma, Inc.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Oculopharyngeal Muscular Dystrophy
Start date
2023-11-28
Primary completion
2030-11-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.